You are here

Patient Enrollment Commences for Phase II Trial of Aurexis, Monoclonal Antibody Therapy for Bloodstream Infection

ATLANTA, March 8 /PRNewswire/ -- Inhibitex, Inc., today announced that it has commenced enrollment in a Phase II clinical trial for Aurexis(R), a humanized monoclonal antibody being developed as a first-line therapy, in combination with standard of care antibiotics for serious, life threatening Staphylococcus aureus (S. aureus) bloodstream infections in hospitalized patients. The Phase II trial will enroll up to 60-patients in a multi-center, randomized, double-blind, placebo-controlled study. Hospitalized patients will be randomized to receive standard of care antibiotic therapy combined with either Aurexis(R) or placebo. The Phase II trial is designed to evaluate the safety, pharmacokinetics and preliminary efficacy of Aurexis(R).

In 2002, there were approximately 225,000 hospital-associated S. aureus in the United States, of which approximately 50,000 were serious bloodstream infections. Studies have indicated that the mortality rate associated with methicillin resistant S. aureus or MSRA bloodstream infections is as high as 40%.

Source: Inhibitex, Inc.

Recent Headlines

Two-Thirds of U.S. Alzheimer’s Cases Are Women, And It’s Not Just Because They Live Longer
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
Breast Cancer, Gastrointestinal Tumors Most Common Types
NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens